COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #83 of 264
7/10 Late treatment study
Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185 (Peer Reviewed)
COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Source   PDF   Share   Tweet
Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication.

Cravedi et al., 7/10/2020, retrospective, USA, multiple countries, North America, multiple regions, peer-reviewed, mean age 60.0, 25 authors.
risk of death, 53.0% higher, RR 1.53, p = 0.17, treatment 36 of 101 (35.6%), control 10 of 43 (23.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit